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The increased risk of cardiovascular disease (CVD) and vascular dysfunction that 
is associated with postprandial hyperglycemia and hypertriglyceridemia may be reduced 
with consumption of non-fat dairy products.  Due to the insulinotropic effect of milk-
derived proteins, postprandial hyperglycemia has been shown to be reduced with the 
addition of dairy products. The purpose of Study 1 was to determine if one serving of 
non-fat milk added to an oral glucose tolerance test (OGTT) could attenuate postprandial 
hyperglycemia in individuals with elevated android adiposity independent of the effects 
of the milk’s protein content and whether these improvements would be associated with 
metabolic and/or peripheral hemodynamic effects.  In this placebo controlled, 
randomized, crossover experimental study, twenty-nine overweight/obese adults 
consumed an OGTT combined with either non-fat milk or a placebo control. In the whole 
sample, blood glucose and insulin concentrations increased over time in both trials with 
no differences between trials. When the subjects were divided into tertiles of android 
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body fat, the highest tertile displayed attenuated hyperglycemic responses as well as 
improvements in flow-mediated dilation during the milk intervention.   
Repeated exposure to elevated postprandial triglycerides, as seen with typical 
Western diets, contributes to atherosclerosis and vascular disease. The purpose of Study 2 
was to determine if a single serving of non-fat milk added to a high fat meal could 
attenuate postprandial hypertriglyceridemia in individuals who consume a high fat diet. 
In this placebo controlled, randomized, crossover experimental study, thirty 
overweight/obese adults consumed a high fat meal combined with either non-fat milk, 
carbohydrate control, or caloric control. In the whole sample, plasma triglycerides 
increased over time with no differences between interventions. When participants were 
ranked and divided based on habitual dietary fat intake, the high fat diet group exhibited 
reduced triglycerides when supplemented with non-fat milk. No differences in 
hemodynamic measures (brachial flow-mediated dilation and femoral vascular 
conductance) were observed between the milk and caloric control trials for either the low 
fat or high fat diet groups.   
Taken together, the results indicate that a single serving of non-fat milk may 
attenuate acute hyperglycemia and hypertriglyceridemia in individuals that present with 
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While often referred to as a single entity, Metabolic Syndrome (MetS) is actually a 
constellation of interrelated metabolic risk factors that promote atherosclerotic cardiovascular 
disease (CVD) and type 2 diabetes mellitus [1, 2]. Two predominant risk factors contributing to 
MetS are insulin resistance and atherosclerosis; the cause and effect of both are intricately involved 
in postprandial metabolism [3-5]. Insulin resistance, a recognized hallmark feature of abnormal 
metabolic function, is characterized by excessive insulin secretion and/or impaired insulin 
signaling [6, 7]. Abnormal insulin response, including insulin resistance, leads to metabolic 
disturbances, including hyperglycemia, hyperinsulinemia, and hypertriglyceridemia that are 
maintained in a perpetual cycle of metabolic dysfunction [7].   
Atherosclerosis is a form of chronic inflammation of the blood vessel walls that can lead 
to ischemia, end-organ damage, stroke, or myocardial infarction. The initial insult is the 
translocation of an LDL cholesterol molecule into the sub-endothelial space causing damage to the 
endothelium, the innermost lining of a blood vessel. This incites an inflammation and immune 
response that leads to invagination of the vessel lumen, resulting in reduced blood flow [1, 8, 9]. 
Eventually, the endothelium undergoes phenotypical alterations to this non-adaptive state known 
as “endothelial dysfunction.” Indeed, endothelial dysfunction is evident prior to any clinical 
symptoms associated with atherosclerosis and has been shown to be associated with an increased 
risk of CVD [10-12]. 
Traditionally, fasting plasma glucose and triglyceride levels have also been used as clinical 
determinants of CVD. However, as most individuals spend the majority of their time in a 
postprandial state, acute responses in plasma glucose and triglycerides following a meal have been 




hour glucose concentration measured during an oral glucose tolerance test (OGTT) is an 
independent predictor of CVD risk, whereas fasting glucose is not, and postprandial triglycerides 
are better predictors of atherosclerosis and coronary artery disease (CAD) than fasting levels [16-
18].  
The pathogenesis of both insulin resistance and atherosclerosis has been attributed to acute 
states of hyperglycemia and hypertriglyceridemia. Increases in postprandial plasma glucose or 
triglyceride concentrations following a high carbohydrate or high fat meal contribute to a pro-
atherogenic metabolic state [19-21].  Moreover, both postprandial lipemia and hyperglycemia are 
associated with reduced vascular reactivity and impaired endothelial function [22, 23]. 
Importantly, while the exact mechanisms have yet to be described, the relation between 
postprandial metabolic impairments and endothelial dysfunction has been firmly established. 
 Epidemiological studies suggest that chronically high consumption of milk and dairy 
products are associated with a reduced risk of diabetes and CVD and are inversely associated with 
MetS [24-28]. The addition of dairy products to a meal high in carbohydrates may potentially 
lessen the risk of diabetes through reductions in postprandial glucose and triglycerides [29-33]. 
Several bioactive compounds found in dairy may possess functional properties although the 
identification of the exact component responsible for reduced postprandial glycemia is difficult to 
ascertain. However, the insulinotropic properties of milk proteins may be a potential mechanism 
to explain, at least in part, the inverse relationship between dairy consumption and cardiometabolic 
diseases [30, 31].  
Furthermore, the increased insulin response associated with milk may aid in postprandial 
vasodilation [34]. Insulin receptors are found on endothelial and vascular smooth muscle cells and 




increase limb blood flow and capillary recruitment for nutrient disposal [35, 36]. This increased 
clearance of glucose and triglycerides may lead to an attenuated impairment of postprandial 
vascular dysfunction. However, the precise mechanisms whereby milk and dairy products exert 
beneficial effects on metabolism and vascular health are unclear. The focus of this review is to 
evaluate the relationships between metabolic dysfunction, postprandial metabolism, and vascular 
dysfunction and to discuss the potential role of milk in attenuating these impairments. 
PURPOSES AND HYPOTHESES 
 
It is well accepted that the progression of atherosclerosis is primarily a postprandial 
phenomenon [37]. Indeed, postprandial triglyceride levels are better predictors of atherosclerosis 
and coronary artery disease than fasting triglycerides [16, 17].  In addition, epidemiological data 
indicates that postprandial hyperglycemia is associated with increased risk of CVD and mortality 
[18, 38, 39].  Chronically high consumption of milk and milk products are associated with a 
reduced risk of diabetes [24-26] and CVD [40] and have an inverse relationship with MetS [27]. 
A potential mechanism underlying how dairy products may reduce the risk of metabolic 
dysfunction is thought to be through reductions in postprandial rise in glycemia and 
triglyceridemia when milk and milk products are consumed [30, 31]. Despite their low glycemic 
index, milk products are insulinotropic, and the associated postprandial insulinemia may facilitate 
the clearance and storage of glucose and triglycerides after a meal [29, 41, 42]. However, the 







The purpose of study #1 was to determine the effect of non-fat milk in attenuating the 
postprandial hyperglycemic surge and its associated physiological mechanisms. We hypothesized 
that consuming one serving of non-fat milk with a standard oral glucose tolerance test (OGTT) 
would attenuate postprandial hyperglycemia. Additionally, we hypothesized that the postulated 
improvement would be associated with increased postprandial insulin secretion as well as insulin-
mediated endothelial vasodilation and whole-limb perfusion. 
 
Study #2: 
The purpose of the study #2 was to determine the effect of non-fat milk on attenuating the 
postprandial surge in plasma triglycerides after a high fat meal and its associated physiological 
mechanisms. We hypothesized that consuming one serving of non-fat milk with a high fat 
tolerance test (HFTT) would attenuate postprandial hypertriglyceridemia. Additionally, we 
hypothesized that the postulated improvement in postprandial metabolic response due to the 
consumption of non-fat milk would be associated with increased postprandial insulin secretion as 
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Background/Aims: Elevated android body fat increases the risk of developing cardiometabolic 
diseases. Postprandial hyperglycemia contributes to the pro-atherogenic metabolic state evident in 
android adiposity. Due to the insulinotropic effect of milk-derived proteins postprandial 
hyperglycemia has been shown to be reduced with the addition of dairy products. The purpose of 
this study was to determine if one serving of non-fat milk added to an oral glucose tolerance test 
(OGTT) could attenuate postprandial hyperglycemia in individuals with elevated android adiposity 
independent of the effects of the milk’s protein content and whether these improvements would be 
associated with metabolic and/or peripheral hemodynamic effects.  Methods: In this placebo-
controlled, randomized, crossover experimental study, 29 overweight/obese adults (26±1 y) 
consumed an OGTT beverage (75 g glucose) combined with either non-fat milk (227 g) or a 
placebo control (12 g lactose + 8 g protein + 207 g water). Results:  In the whole sample, blood 
glucose and insulin concentrations increased over time in both trials with no significant differences 
between trials. Relative increases in peak blood glucose response were significantly related to 
android body fat (p<0.05). When the subjects were divided into tertiles of android body fat, the 
highest tertile displayed attenuated hyperglycemic responses as well as improvements in flow-
mediated dilation during the milk intervention.  Conclusions: The present findings indicate that a 
single serving of non-fat milk may attenuate acute hyperglycemia in individuals with elevated 





Obesity has long been accepted as a clinical risk factor for cardiovascular and other chronic 
diseases [43, 44]. In particular, android obesity is associated with greater risk of developing 
cardiometabolic diseases than other adipose storage patterns [45] as it exacerbates metabolic 
disturbance [46].  The visceral adipose tissue that coexists with android obesity is associated with 
insulin resistance as well as reduced glucose disposal and oxidation [47]. Traditionally, fasting 
plasma glucose has been used as a clinical determinant of CVD risk.  However, as individuals 
spend the majority of their time in a postprandial state, acute responses to plasma glucose following 
an oral glucose tolerance test (OGTT) are better predictors of relative CVD risk [18].  Indeed, 
increases in postprandial hyperglycemia following a high carbohydrate meal contribute 
importantly to a pro-atherogenic metabolic state [21] in part through attenuating endothelium-
dependent vasodilation [23, 48].  
Chronically high dairy consumption is inversely associated with the risk of metabolic 
syndrome, type 2 diabetes, and CVD [30, 31]. Importantly, the beneficial effects of dairy on 
metabolic and clinical parameters are evident in individuals with elevated risk for CVD [27, 49]. 
However, there appears to be a distinct “floor effect” associated with dairy intake, in which little 
to no changes were observed in relatively healthy individuals with normal or low baseline levels 
[50].   The complete mechanism underlying the association between dairy intake and 
cardiometabolic diseases is not clear.  However, dairy products may attenuate the risk of metabolic 
dysfunction through reductions in postprandial glycemia when milk and milk products are 
consumed with a meal.  Recent research has demonstrated favorable effects in glycemic 
management when dairy products are combined with high carbohydrate meals [51, 52]. The 
majority of relevant findings in this area attribute attenuated hyperglycemia to the insulinotropic 




in postprandial hyperglycemia when consumed with a high carbohydrate meal [53]. However, no 
study has yet investigated whether milk can attenuate postprandial hyperglycemia independent of 
its protein component. Additionally, it is unknown if the beneficial effects of milk are mediated 
by changes in peripheral vasodilation and hemodynamics.   
Therefore, the purpose of this study was to determine whether a serving of non-fat milk 
could attenuate postprandial hyperglycemia independent of its protein content. The effect of non-
fat milk was compared with a placebo drink matched for macronutrient and caloric content in a 
double-blind fashion. In this study design, any differences in postprandial hyperglycemia between 
the non-fat milk and placebo trials could not be attributed to the macronutrient, and specifically 
the protein content, of milk. Because postprandial metabolism is affected greatly by diet and 
physical activity, these lifestyle factors were tightly controlled. Since android obesity is associated 
with poorer metabolic health, we sought to determine the influence of android body fat on the 
milk’s ability to reduce postprandial hyperglycemia. Based on the observation that the effects of 
dairy intake do not appear to manifest in relatively healthy individuals [50], we hypothesized that 
milk would attenuate an acute hyperglycemic load compared with a macronutrient, caloric control 
preferentially in individuals with the greatest level of adiposity. Moreover, we posited that these 
postulated improvements would be associated with peripheral vasodilation. 
METHODS 
Study Population.  A total of 29 adults with a mean (±SEM) age of 26±1 y were studied. 
Participants were recruited via advertisements and fliers from the local community. Inclusion 
criteria were as follows: apparently healthy, sedentary (physical activity <3 d/wk), overweight or 
obese (BMI ≥ 25.0 kg/m2), nonsmokers, no overt signs of chronic diseases on physical examination 




no cardiovascular-acting medications, and no pregnancy.  Participants who were lactating or 
presented with dairy allergies, lactose intolerance, or alcohol abuse were excluded from the study. 
Participants were required to maintain their normal routine diet and exercise habits for the duration 
of the study. After being informed about the study verbally and in writing, all participants gave 
their informed consent. All procedures were reviewed and approved by the Internal Review Board 
at The University of Texas at Austin. 
 Study Design.  A placebo-controlled, randomized, crossover experimental design was used 
for the present investigation. Each participant underwent both non-fat milk and placebo treatments 
with an oral glucose tolerance test (OGTT).  Each treatment was preceded by two consecutive days 
of diet and physical activity controls. Treatments were separated by a washout period of at least 1 
week.  
 Experimental Protocol.  During the screening visit, body composition was assessed using 
dual-energy X-ray absorptiometry (DXA; see below).  This was done to calculate daily caloric 
requirements for the standardized meals.  Standardized meals were matched for energy content 
(isocaloric; 60% carbohydrate, 15% protein, and 25% fat) and were provided to participants to 
consume on Days 1-2.   The participants were provided with a dietary record log and were 
instructed to consume the same meals and record the timing of the meals on both days to better 
replicate the dietary controls prior to the second treatment. Alcohol and caffeine intake were 
prohibited starting in the evening before Day 1.  In addition to the diet controls, the participants 
were instructed to maintain their normal daily activity but refrain from both formal and recreational 
exercises.  To confirm this, participants were provided with and required to wear pedometers 




 Following these two control days, participants reported to the laboratory on the morning of 
Day 3 for fasted, resting measures followed by one of the treatments. An intravenous catheter was 
inserted into the antecubital vein, and fasting blood samples were collected. Upon conclusion of 
the resting measures, participants consumed a fruit punch flavored, standard OGTT beverage (100 
g glucose) combined and mixed with either: 8 oz of non-fat milk (227 g) or 8 oz of the control 
drink (12 g lactose + 8 g whey protein + 207 g water). The control drink was identical to non-fat 
milk in macronutrient and calorie contents. Participants were instructed to consume the test 
beverages within 5 minutes. After ingestion of test solutions, the participants remained in the 
supine position during the two-hour postprandial period in the quiet, temperature-controlled 
laboratory.  
 Measurements. Body composition and android body fat were estimated noninvasively 
using the total body scan by DXA (GE Lunar, Chicago, IL) [56]. For measuring android fat, a 
region of interest was automatically defined by the software, in which the caudal limit was placed 
at the top of the iliac crest and its height set to 20% of the distance from the top of the iliac crest 
to the base of the skull to define its cephalad limit. During each treatment, blood samples were 
collected at 10, 20, 30, 45, 60, 90, and 120 minutes during the postprandial period.  These samples 
were later analyzed for plasma glucose, insulin, glucagon, and gastric inhibitor polypeptide (GIP) 
concentrations.  Commercially available assay kits were used to determine plasma concentrations 
of glucose (Point Scientific, Canton, MI), GIP (RayBio, Norcross, GA) and insulin (Mercodia, 
Uppsala, Sweden). A commercially available radioimmunoassay kit was used to assess glucagon 
(EMD Millipore, Darmstadt, Germany) [57].  The net incremental area under the curve (iAUC) 
for plasma glucose and insulin was calculated using the trapezoidal method [57] as it was shown 




 Vascular function was measured at baseline, 30 min, and end of the postprandial period 
(120 min).  To assess vascular endothelium-dependent vasodilation, flow-mediated dilation 
(FMD) was performed as previously described [59]. Briefly, brachial artery diameters and blood 
flow velocity were measured from images derived from an ultrasound machine (iE33, Philips 
Medical, Bothel, WA) equipped with a high-resolution linear-array transducer. A longitudinal 
image of the brachial artery was acquired 5-10 cm proximal to the antecubital fossa. A blood 
pressure cuff, placed on the forearm 3-5 cm distal to the antecubital fossa, was inflated to 50 mmHg 
above resting systolic blood pressure or a maximum of 200 mmHg for 5 minutes. After cuff 
deflation, ultrasound-derived measurements of the brachial artery diameters and blood velocity 
were taken for 3 minutes. FMD was calculated as a percent increase in brachial artery diameter at 
the post-blood flow occlusion compared with the pre-blood flow occlusion.  
Blood flow and vascular conductance were measured in the common femoral artery using 
the ultrasound machine (iE33, Philips Medical, Bothel, WA) as previously described [60, 61]. To 
minimize turbulence from the bifurcation, the measurements were performed below the inguinal 
ligament, approximately 2-3 cm above its bifurcation into the profundus and superficial branch.  
Mean blood velocity measurements were performed with the insonation angle <60 degrees.  Blood 
flow was calculated from the following formula: (mean blood velocity) x (circular area) x 6 x 104.  
The data were analyzed by the same investigator, who was blinded to the identity of the participant 
and the treatment.  Femoral artery vascular conductance was calculated as femoral blood flow / 
mean arterial pressure. 
Statistical Analyses.  Two-way (treatment x time) ANOVA with repeated measures were 
used to analyze the effects of treatment solutions. Tukey Least Significant Difference Test (LSD) 




glucose, insulin, glucagon, and GIP concentrations were calculated. Linear regression analyses 
were performed to determine associations between insulin and glucose iAUCs for both trials at 30 
and 120 minutes. As well as the relation between relative increases in peak blood glucose 
concentration [(peak blood glucose – baseline blood glucose)/ baseline blood glucose] and android 
body fat levels. Changes in FMD were compared between conditions with paired one-tailed t-test.  
All data were expressed as meansSEM. 
RESULTS 
Selected participant characteristics are reported in Table 1. Despite being overweight and 
obese, all participants had optimal or near optimal blood pressure and fasting blood glucose, lipid, 
and lipoprotein concentrations.  
As shown in Figure 1, blood glucose and insulin concentrations increased over time in both 
the milk and the control drink trials.  There were no significant differences in glucose and insulin 
concentrations or glucose and insulin iAUC between the non-fat milk and control over the two-
hour postprandial period. Glucose iAUC was related to insulin iAUC (R2=0.40, p<0.05) for 30 
minutes, and the association was stronger when the entire 120 minutes were included (r2=0.71, 
p<0.05).  As depicted in Table 2, there were no significant differences in plasma glucagon or GIP 
responses between the test beverages over the two-hour postprandial period. Similarly, there was 
no difference between the test beverages for glucagon or GIP iAUC (data not reported).   
Relative increases in peak blood glucose concentration were significantly related to android 
body fat levels (r=0.27, p<0.05). In order to determine the influence of abdominal body fatness on 
metabolic responses, participants were divided into tertiles of android body fat. The participants 




men and 20% women) displayed attenuated hyperglycemic responses when supplemented with 
non-fat milk, compared with the control beverage (Figure 2).   
 Whole group vascular and hemodynamic measures are presented in Table 3.  Heart rate, 
mean blood pressure, and brachial artery FMD did not change significantly during the observation 
period in both treatments. Femoral artery blood flow and vascular conductance demonstrated time 
effects with no differences between test beverages.  In the sub-group analysis involving the highest 
tertile of android body fat group, FMD was improved (p<0.05) with the milk supplementation 
(Figure 3). 
DISCUSSION 
In the entire sample of overweight and obese participants who had otherwise normal 
metabolic health, there were no differences in metabolic and hemodynamic responses between 
non-fat milk and the control drink that was matched for macronutrient and total calories.  In 
individuals with the highest android obesity, however, non-fat milk attenuated acute 
hyperglycemia. The beneficial effects of dairy intake were associated with the elevated 
endothelium-dependent vasodilation.  These findings suggest that milk consumed with a high 
carbohydrate meal may reduce hyperglycemic responses preferentially in individuals with less 
favorable cardiometabolic profile and that these metabolic effects may be related to hemodynamic 
improvements.    
Previous studies have reported that when low-fat milk was consumed ad-libitum with a 
meal, post-meal blood glucose level was decreased [51, 52].  However, because neither the foods 
nor beverage intakes were controlled, it remains unknown if a single serving of non-fat milk, which 
is typically consumed with a meal, is sufficient to induce suppression of hyperglycemia after the 




carbohydrate meal as well as milk intake.  Additionally, because type and amount of prior physical 
activity and meals could significantly affect postprandial metabolism and vascular responses, we 
implemented strict dietary and physical activity controls prior to each treatment.  We found no 
significant differences in glycemic responses between the trials involving non-fat milk and those 
with the control drink that included the same amount of protein.  These results confirm previous 
findings that at least some of the beneficial effects of milk on glycemic responses can be attributed 
to its protein content [53-55].          
In general, studies investigating the effects of specific milk proteins are more conclusive 
in terms of demonstrating beneficial effects on glycemic responses especially in individuals with 
elevated risks. For example, the consumption of whey protein with a high glycemic meal decreased 
postprandial serum glucose in patients with diabetes [54]. We recruited obese yet young, 
apparently healthy participants that exhibited fairly normal postprandial metabolic and vascular 
responses. However, by selecting individuals with highly elevated android body fat, we observed 
a significant effect of milk on attenuating postprandial hyperglycemia. These results are consistent 
with the previous observation that the beneficial effects of dairy on metabolic and clinical 
parameters are more likely to be evident in individuals with elevated risk factors for CVD as there 
appears to be a distinct “basement effect” associated with dairy intake, in which little to no changes 
have been observed in healthy individuals with normal or low values [27, 49, 50]. Therefore, the 
observed effects can likely be extended to, and perhaps greater in, older obese adults, type 2 
diabetes, and those with CVD.  Clearly, further research in these populations is warranted.    
The protein component in non-fat milk is ~20% whey and ~80% casein protein.  Although 
the total protein content of the control drink was closely matched with non-fat milk, it contained 




causing it to appear in the blood stream sooner.  Whey protein ingestion reduces postprandial 
hyperglycemia without increases in C-peptide release or insulin concentrations suggesting that 
whey may affect glucose clearance by stimulating insulin-independent mechanisms [53, 62]. In 
spite of this, we observed improvements in the early phase of the OGTT in the highest tertile of 
android obesity. Therefore, any insulin-independent effects of whey do not appear to be 
responsible for the observed improvements in glycemic responses.  To the best of our knowledge, 
this is the first study to demonstrate that milk can elicit glycemic improvements independent of 
the macronutrient composition, more specifically protein content. Importantly, previous studies 
investigating the effects of milk and milk protein on postprandial hyperglycemia employed less 
carbohydrate and more protein [53, 54], allowing for a greater potential of protein to limit increases 
in blood glucose.  The present findings indicate that a single serving of milk was effective in 
attenuating the glycemic effect of high carbohydrate meals at least in individuals with highly 
elevated android obesity.    
Other components of milk may be responsible for the attenuated glycemic response.  The 
combined vitamin and mineral content comprises less than 1% of milk, but this rather small volume 
could offer significant functional properties [63]. Oral magnesium supplementation, for example, 
improves insulin sensitivity, glucose homeostasis, and HbA1c levels in diabetic patients [64]. 
Several intervention studies have shown improved glycemic responses with vitamin D treatment, 
but these effects may be specific to individuals who were deficient at baseline or those who had 
preexisting metabolic disorders [63, 65]. The micronutrient profile of dairy could contribute to 
attenuated hyperglycemia as the cellular influx of calcium plays a pivotal role in nutrient intake 
and in endothelial-dependent vasodilation, and magnesium is essential for optimal coupling and 




Nearly all studies showing the beneficial effects of dairy intake have attributed the 
favorable metabolic effects to the insulinotropic properties of milk proteins. Indeed, compared 
with other protein sources, milk demonstrates a larger insulin response up to 240 min post-meal 
[30]. By controlling for the amount of dairy protein in the test beverages, we ensured that any 
positive changes were independent of the effects of milk proteins on insulin secretion. As there 
were no differences in insulin responses between beverages, the effects of dairy on acute 
hyperglycemia in this study appear to be insulin-independent.  
Our integrative physiological approach allowed us to gain insight into potential 
mechanisms underlying the effects of milk on postprandial metabolism. Specifically, we addressed 
the hypothesis that improvements in postprandial hyperglycemia would be associated with 
increases in peripheral perfusion and vasodilation. Compared with an isocaloric volume of rice 
milk, obese individuals demonstrate improved endothelial-dependent vasodilation with low-fat 
milk [67]. However, neither a meal nor the carbohydrate or protein differences were controlled 
between the test beverages. Additionally, whey-derived protein elicited improved endothelium-
dependent vasodilation at 120 minutes in mildly hypertensive, overweight participants [68]. We 
also observed the beneficial effect of milk intake on FMD at the end of the OGTT although blood 
glucose concentration was no longer different between the trials.  One may argue that the reduced 
glycemic load at 30 minutes may have elicited a delayed effect in improved vasodilation that 
became evident at 120 minutes.  Nevertheless, the improvement in FMD implies vascular 
protective effects of milk and significant therapeutic applications for at-risk individuals.   
 Importantly, the present findings are the first to demonstrate that non-fat milk is capable of 
attenuating postprandial hyperglycemia independent of the hypoglycemic effects of dairy protein 




attenuating postprandial hyperglycemia offers tremendous potential to reduce future CV risks. The 
present findings indicate that a single serving of non-fat milk was sufficient to attenuate acute 
hyperglycemia at least in individuals with highly elevated android obesity. This offers a simple, 
convenient, and easily implemented option for managing elevations in blood glucose in individuals 
at high risk for developing CVD.  
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Table 1. Selected Participant Characteristics. 
Variable Mean ± SEM 
Age (yr) 26 ± 1 
Men/Women (n) 17/12 
Height (cm) 172 ± 1 
Body Weight (kg) 92.7 ± 2.0 
BMI (kg/m2) 31.6 ± 0.9 
Total Body Fat (%) 39 ± 2 
Android Body Fat (%) 48 ± 2 
Systolic BP (mmHg) 116 ± 2 
Diastolic BP (mmHg) 77 ± 2 
Total Cholesterol (mg/dl) 180 ± 8 
LDL Cholesterol (mg/dl) 108 ± 7 
HDL Cholesterol (mg/dl) 48 ± 7 
Triglycerides (mg/dl) 107 ± 17 
Blood Glucose (mg/dl) 92 ± 2 
(n=29); BMI = body mass index, BP = blood pressure, LDL = low density lipoprotein, HDL = 







Table 2. Changes in metabolic hormone concentrations throughout the oral glucose tolerance 
test (OGTT) with non-fat milk or the control drink. 
Measure Trial Oral Glucose Tolerance Test 
  0 10 20 30 45 60 90 120 
          
Glucagon Milk 106 ± 5 106 ± 5 100 ± 5*
† 93 ± 5*†‡ 91 ± 6*†‡ 91 ± 5*†‡ 87 ± 5*†‡§ 86 ± 5*†‡§ 
(pg/mL) Control 107 ± 5 109 ± 5 104 ± 5† 93 ± 4*†‡ 91 ± 4*†‡ 89 ± 4*†‡ 82 ± 5*†‡§¶# 83 ± 4*†‡§¶# 
          
GIP Milk 18 ± 3 -------- -------- 19 ± 3 -------- 18 ± 2 -------- -------- 
(pmol/L) Control 19 ± 3 -------- -------- 18 ± 3 -------- 17 ± 3 -------- -------- 
          
GIP = gastric inhibitory peptide, * compared with baseline, † Compared with 10 minutes, ‡ 
compared with 20 minutes, § compared with 30 minutes, ¶ compared with 45 minutes, # compared 





Table 3. Changes in vascular and hemodynamic measures at baseline and at the end of the oral 
glucose tolerance test (OGTT) with non-fat milk or the control drink. 
Measure Trial OGTT 
  Baseline 30 min 120 min 
Mean Blood Pressure Milk 84 ± 3 81 ± 2 79 ± 3 
(mmHg) Control 85 ± 2 83 ± 1 77 ± 4 
     
Heart Rate Milk 72 ± 3 70 ± 2 71 ± 2 
(bpm) Control 68 ± 2 71 ± 2 71 ± 2 
     
Brachial Flow-Mediated Milk 7.6 ± 0.6 8.4 ± 0.6 8.4 ± 0.6 
Dilation (%) Control 8.7 ± 0.6 7.1 ± 0.6 8.0 ± 0.7 
     
Femoral Blood Flow Milk 482 ± 42 313 ± 28* 413 ± 45† 
(ml/min) Control 463 ± 52 310 ± 31* 353 ± 27* 
     
Femoral Vascular Milk 5.9 ± 0.6 3.8 ± 0.4* 4.9 ± 0.5 
Conductance (AU) Control 5.6 ± 0.7 3.7 ± 0.4* 4.4 ± 0.4 
 






Figure 1. Whole group glucose and insulin response. 
Changes in blood glucose and insulin concentrations during the OGTT with non-fat milk or the 













































Figure 2. Subgroup blood glucose response.  
Changes in blood glucose concentration and mean glucose integrated area under the curve 
(iAUC) at 30 minutes during the OGTT with non-fat milk or the control drink in the participants 
in the highest android body fat tertile (n=10). Values are mean ± SEM. 
 
  













































Figure 3. Subgroup flow-mediated dilation. 
Change in flow-mediated dilation (FMD) from baseline to the end of the OGTT with non-fat 
milk or the control drink in the participants in the highest android body fat tertile (n=10). Values 


















NON-FAT MILK IMPROVES ACUTE HYPERTRIGLYCERIDEMIA IN 
INDIVIDUALS WITH CHRONIC CONSUMPTION OF HIGH FAT DIET  
 
ABSTRACT 
Background/Aims: Repeated exposure to elevated postprandial triglycerides, as seen with 
typical Western diets, contributes to atherosclerosis and vascular disease. The purpose of this study 
was to determine if a single serving of non-fat milk added to a high fat tolerance test could attenuate 
postprandial hypertriglyceridemia in individuals who consume a high fat diet. Methods: In this 
placebo-controlled, randomized, crossover experimental study, 30 overweight/obese adults 
consumed a high fat tolerance test meal combined with either non-fat milk, carbohydrate control 
(CHO), or caloric control (CAL). Results: In the whole sample, plasma triglycerides increased 
over time with no significant differences between interventions. Peak plasma triglyceride levels 
were significantly related to dietary fat intake (r=0.30, p<0.05).  When participants were ranked 
and divided into tertiles based on habitual dietary fat intake, the high fat diet group exhibited 
reduced triglyceride net integrated area under the curve (iAUC) when supplemented with non-fat 
milk. No significant differences in hemodynamic measures (brachial flow-mediated dilation and 
femoral vascular conductance) were observed between the milk and caloric control trials for either 
the low fat or high fat diet groups.  Conclusions: A single serving of non-fat milk may attenuate 
acute hypertriglyceridemia in individuals who chronically consume a high fat diet, offering a 






Atherosclerosis is responsible for over 40% of deaths in the U.S. [69]. Traditionally, fasting 
plasma triglyceride has been used as an important risk factor for atherosclerosis. However, as most 
individuals spend the majority of their awakening time in a postprandial state, acute responses in 
plasma triglycerides following a meal have been shown to be better predictors of relative 
cardiovascular disease (CVD) risk [14, 15]. Indeed, postprandial lipemia is associated with 
reduced vascular reactivity and impaired endothelial function [22, 70, 71]. The magnitude of 
increase in postprandial plasma triglycerides is directly proportional to the fat content in meals 
[20, 72, 73]. As such, multiple high fat meals throughout the day exemplified by typical Western 
diets results in the prolonged presence of elevated plasma triglycerides. Repeatedly exposing the 
vasculature to hypertriglyceridemia causes endothelial dysfunction, which may increase the risk 
of developing atherosclerosis. 
Epidemiological studies suggest that chronically high consumption of milk and dairy 
products are inversely associated with the overall risk of atherosclerosis [27, 28, 49, 74, 75]. A 
potential mechanism underlying how dairy products reduce the risk of atherosclerosis may be 
through the attenuation in the postprandial rise in triglyceridemia when milk and milk products are 
consumed with a high fat meal [30, 33, 76, 77].  However, the available evidence is inconclusive 
and highly controversial. For example, the postprandial appearance of triglycerides was decreased 
with the consumption of large doses of milk-derived proteins [77]. In contrast, no difference was 
found in postprandial triglycerides between milk, a carbohydrate control, and a caloric control 
[33].  
Milk proteins demonstrate an insulinotropic effect upon absorption in the gut that may 
induce the rapid release of insulinotropic amino acids and gastric inhibitor polypeptide (GIP), 




through a nitric oxide dependent mechanism, postprandial hyperinsulinemia and the resultant 
vasodilation could be a mechanism underlying the potential effect of milk protein on postprandial 
hypertriglyceridemia [35]. However, hemodynamic studies have not been performed in 
conjunction with the effects of milk and milk proteins to confirm this possibility.  
Thus, the main aim of the present study was to determine if a single serving of non-fat milk 
could attenuate postprandial hypertriglyceridemia induced by a high fat tolerance test in 
individuals who chronically consume a high fat diet. Overweight and obese individuals who 
consume high fat diets are at an increased risk of developing atherosclerosis [78] and often present 
with sub-optimal metabolic profiles.  These individuals may be the biggest beneficiaries of the 
proposed dietary regimen.  Accordingly, participants were ranked and divided into tertiles based 
on habitual dietary fat intake. As secondary outcomes, we also evaluated whether these 
improvements would be associated with hyperinsulinemic and/or vasodilatory effects, including 
endothelial-dependent vasodilation and whole limb perfusion.  Employing a carbohydrate control 
and a macronutrient/caloric control allowed us to determine whether milk, independent of its 
protein content, was capable of attenuating postprandial triglyceride response. 
METHODS 
Participants.  A total of 30 young adults with a mean (±SEM) age of 26±1 y were studied. 
They were recruited via advertisements and fliers from the local community. Inclusion criteria 
were as follows: healthy, sedentary (physical activity <3 d/wk), overweight or obese (BMI ≥ 25.0 
kg/m2), nonsmoking, no overt signs of chronic diseases as assessed by physical examination and/or 
medical health history, normal blood chemistry as assessed by fasting glucose and lipid panel, no 
cardiovascular-acting medications, and no pregnancy.  Participants who were lactating or reported 




Participants were required to maintain their normal routine diet and exercise habits for the duration 
of the study participation. After being informed about the study verbally and in writing, all 
participants gave their informed consent. All procedures were reviewed and approved by the 
Internal Review Board. 
 Study Design.  A placebo-controlled, randomized, crossover experimental design was used 
for the present dietary intervention trials. Each participant underwent the following treatments: 
non-fat milk, a carbohydrate control, and a total caloric control.  Each treatment was preceded by 
two consecutive days of strict dietary and physical activity controls. Treatment interventions were 
randomized and separated by a washout period of at least 1 week.  
 Experimental Protocol. Dietary intake was reported with a 3-day, self-report food log and 
analyzed by a registered dietician with Nutrition Pro Software (Axxya Systems, Woodinville, 
WA). During the screening visit, body composition was estimated noninvasively using the total 
body scan by dual energy x-ray absorptiometry (GE Lunar, Chicago, IL) [56].  This was done prior 
to the study to calculate daily caloric requirements for the standardized meals given prior to the 
main protocol.  Standardized meals were matched for energy/calorie content (isocaloric; 60% 
carbohydrate, 15% protein, and 25% fat) and were provided to participants to consume on Days 
1-2.   The participants were provided with a dietary record log and instructed to consume the same 
meals and record the timing of the meals on both days to better replicate the dietary controls prior 
to the other treatments. Alcohol and caffeine intake were prohibited starting in the evening before 
Day 1.  In addition to the dietary controls, the participants were instructed to maintain their normal 
physical activity, but refrain from both formal and recreational exercises.  To confirm this, 
participants were provided with and required to wear pedometers during the waking hours of Days 




 Following these two control days, participants reported to the laboratory on the morning of 
Day 3. Following the resting measurements of vascular functions, an intravenous catheter was 
inserted into the antecubital vein, and fasting blood samples were collected. Upon conclusion of 
these resting measures, participants consumed a high fat meal consisted of corn chips (H.E.B., San 
Antonio, TX), which were 68% fat/serving. To normalize the high fat load, participants were given 
1 g of dietary fat/kg of body weight. This high fat meal was provided with 8 oz of non-fat milk 
(227 g liquid weight), 8 oz of carbohydrate (CHO) control drink (12 g lactose + 215 g water), or 8 
oz of the caloric (CAL) control drink (12 g lactose + 8 g whey protein + 207 g water). The 
carbohydrate control drink was identical to non-fat milk in carbohydrate content, and the caloric 
control drink was identical to non-fat milk in macronutrient and calorie contents. Participants were 
instructed to consume the test meal and beverage within 20 minutes. After ingestion of test meal 
and beverages, the participants remained sedentary in the quiet, temperature-controlled laboratory 
during the 4-hour postprandial period. 
 Measurements. During each treatment, blood samples were collected at baseline, 30, 60, 
90, 120, 180, and 240 minutes during the postprandial period.  These samples were later analyzed 
for plasma glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), and gastric inhibitor 
polypeptide (GIP) concentrations. Due to financial constraint, GLP-1 and GIP concentrations were 
analyzed only for baseline, 30, 60, and 120 minutes. These time points were selected because 
significant changes in these hormones were expected to occur early in the postprandial phase. 
Commercially available assay kits were used to determine triglyceride and glucose concentrations 
(Point Scientific, Canton, MI). Enzyme-linked immunosorbent assays were used to assess plasma 
concentrations of GIP and GLP-1 (RayBiotech, Inc., Norcross, GA) and insulin (Mercodia, 




Millipore, Darmstadt, Germany) [57].  The net incremental area under the curve (iAUC) for plasma 
triglycerides was calculated using the trapezoidal method [57].  
 Vascular function was measured at baseline, midway (120 min), and end of the 
postprandial period (240 min).  As an index of vascular endothelium-dependent vasodilation, flow-
mediated dilation (FMD) was measured as previously described [59]. Briefly, brachial artery 
diameter and blood flow velocity were assessed from images derived from an ultrasound machine 
(iE33, Philips Medical, Bothel, WA) equipped with a high-resolution linear-array transducer. A 
longitudinal image of the brachial artery was acquired 5-10 cm proximal to the antecubital fossa. 
A blood pressure cuff, placed on the forearm 3-5 cm distal to the antecubital fossa, was inflated to 
50 mmHg above resting systolic blood pressure or a maximum of 200 mmHg for 5 minutes. After 
cuff deflation, ultrasound-derived measurements of the brachial artery diameters and blood 
velocity were taken for 3 minutes. FMD was calculated as a percent increase in brachial artery 
diameter at the post-blood flow occlusion compared with the pre-blood flow occlusion.  
Blood flow and vascular conductance were measured in the common femoral artery using 
the ultrasound machine (iE33, Philips Medical, Bothel, WA) as previously described [60, 61]. To 
minimize turbulence from the bifurcation, the measurements were performed below the inguinal 
ligament, approximately 2-3 cm above its bifurcation into the profundus and superficial branch.  
Mean blood velocity measurements were performed with the lowest possible insonation angle that 
was always <60 degrees.  Blood flow was calculated using the following formula: (mean blood 
velocity) x (circular area) x 6 x 104.  The data were analyzed by the same investigator, who was 
blinded to the identity of the participant and the treatment.  Femoral artery vascular conductance 




Statistical Analyses.  All data were expressed as meanSEM. Two-way (treatment x time) 
ANOVA with repeated measures were used to analyze the effects of treatments on vascular, 
hemodynamic, and metabolic measures. Tukey’s Least Significant Difference (LSD) test was used 
for all post-hoc comparisons. Participants were ranked based on dietary fat intake from the normal 
diet as self-reported in the 3-day food log and divided into tertiles for analyses. Differences in 
triglyceride iAUC were compared between subgroups with paired two-tailed t-tests. Linear 
regression and correlation analyses were performed to determine the relationship between 
metabolic measures.  
RESULTS 
Selected participant characteristics are reported in Table 1. Average BMI of the participants 
was in the obese category.  Despite being obese or overweight, all participants had normal blood 
pressure and fasting blood glucose, lipid, and lipoprotein concentrations.  
During the high fat tolerance test (HFTT), plasma triglyceride concentrations increased 
over time in all trials with no significant differences between milk and control treatments at any 
time point (Figure 1A).  Moreover, there were no significant differences in triglyceride iAUC 
between the test beverages over the four-hour postprandial period although there was a trend for 
milk to reduce triglyceride iAUC (Figure 1B).  
Plasma glucose and hormone concentrations are presented in Table 2. Plasma glucose and 
insulin peaked at 30-60 minutes exhibiting significant time effects for all treatments with no 
differences between tests. GIP concentration increased (P<0.05) for all treatments, whereas GLP 




Vascular and hemodynamic measures are presented in Table 3. Mean arterial pressure, 
heart rate, and brachial FMD did not change during the HFTT in any trials. Vascular conductance 
and femoral blood flow decreased significantly only in the milk and carbohydrate control trials.  
When correlational analyses were performed, peak plasma triglyceride levels during the 
HFTT were significantly related to dietary fat intake (r=0.30, p<0.05). The participants were 
ranked and divided into tertiles of dietary fat intake based on the self-reported 3-day food logs.  
The low fat diet group (40% men and 60% women) consumed 16% protein, 50% carbohydrate, 
and 34% fat in their regular diets.  The high fat group (70% men and 30% women) consumed 17% 
protein, 39% carbohydrate, and 44% fat. There were no significant differences in gender/sex, body 
weight, or BMI between the groups. As shown in Figure 2, compared with the caloric control 
beverage, the high fat diet group exhibited reduced triglyceride responses when supplemented with 
milk.  No such trend was observed in the low fat diet group.  When hypotriglyceridemic effects of 
the milk were calculated by subtracting the effects from calorie control, such effects were 
significant only in the high fat diet group. No differences were observed in insulin concentrations 
or iAUC between the milk and caloric control trials for either the low fat or high fat diet groups. 
Similarly, for vascular and hemodynamic measures, no differences were observed between the 
milk and caloric control trials for either the low fat or high fat diet groups. 
DISCUSSION 
In the entire sample of overweight and obese participants who had otherwise normal 
metabolic health, there were no differences in metabolic and hemodynamic responses between 
non-fat milk and the control drinks. However, when participants were divided into tertiles of 




consumed a high fat diet. These findings suggest that non-fat milk consumed with a high fat meal 
reduces the hypertriglyceridemic response in individuals who regularly consume a high fat diet.    
 Our whole group findings that milk does not reduce postprandial triglyceride response 
compared with carbohydrate or macronutrient/caloric controls are in agreement with previous 
findings [33]. However, in analyzing the whole group data, we identified dietary fat intake to be a 
dominant factor predicting postprandial triglyceride response as evidenced by a highly significant 
association between the two.  We then divided participants into tertiles of dietary fat intakes and 
demonstrated that in those individuals who habitually consumed a high fat diet, a high fat tolerance 
meal with a macronutrient/caloric control beverage elicited a larger increase in postprandial 
triglycerides compared with the low fat diet group. However, the larger postprandial triglyceride 
response was attenuated with the non-fat milk treatment, suggesting that non-fat milk does offer a 
hypotriglyceridemic effect in those individuals who habitually consume typical Western diets. 
 The lipid lowering effects seen in the present study may be attributed to dairy’s 
insulinotropic properties. Compared with other protein sources, milk demonstrates a larger insulin 
response up to 240 min post-meal [30].   Increased insulin concentration during postprandial 
lipemia limits the hydrolysis and release of stored triglycerides by inhibiting hormone sensitive 
lipase. Insulin also stimulates lipoprotein lipase causing the hydrolysis and release of triglycerides 
from lipoproteins for storage [79]. However, there were no differences in insulin response between 
trials suggesting that insulin may not be the mediating factor eliciting the hypotriglyceridemic 
response of the non-fat milk intervention in the present study. 
 In the sub-group analyses using tertiles, the macronutrient/caloric control beverage used in 
this study was not as effective as non-fat milk in eliciting reductions in postprandial triglycerides 




constituents between the two beverages. While the total protein content was matched, non-fat milk 
consists of 80% casein whereas the macronutrient/caloric control was 100% whey.  Casein is a 
slowly digested protein compared with whey and remains in the stomach longer. During a high 
energy, mixed meal, the larger casein content in the milk trial likely delayed gastric emptying and 
reduced the absorption of dietary fat [80]. Therefore, the reduced triglyceride response during the 
non-fat milk trial may be mediated by a higher casein content compared with the 
macronutrient/caloric control trial.   
 Additionally, the micronutrient profile present in the non-fat milk intervention may have 
contributed to the reduction in postprandial triglycerides. A recent review reported that the inverse 
relationship between serum vitamin D status and metabolic syndrome may be mediated by reduced 
hyperlipidemia [81]. Additionally, it has been proposed that the high calcium content in dairy 
benefits the serum lipid profile. The proposed physiological mechanism is that calcium binding to 
saturated fatty acids within the intestines forms insoluble soaps that are excreted in the feces. 
Healthy men consuming milk or yogurt daily containing calcium demonstrated increased fecal 
fatty acid and bile acid excretion and lower fat absorption during dairy intake [82]. And finally, 
magnesium has been shown to reduce serum triglycerides, in patients with ischemic heart disease 
[83], presumably through modifications of several enzymes intricately linked with lipid 
metabolism [84]. 
Chronically high dairy consumption is inversely associated with the risk of metabolic 
syndrome, type 2 diabetes, and CVD [30, 31]. The beneficial effects of dairy intake on metabolic 
and clinical parameters are evident in individuals with elevated risk for CVD [27, 49], but minimal 
or negligible in relatively healthy individuals [50].   This “baseline effect” may explain our present 




because, despite being overweight/obese, the lower dietary fat intake maintained a more optimal 
metabolic profile, as evident by lower fasting triglycerides. 
There are very few previous studies that have examined the effect of complete dairy 
products on postprandial triglycerides. Most of these studies suffer from a lack of proper controls 
prior to and/or during the interventions [32, 33]. For instance, a study comparing the effects of a 
high fat dairy meal, a high fat non-dairy meal served with whole-fat milk, and a high fat non-dairy 
control meal, found neither dairy meal exhibited different postprandial triglyceride response 
compared with the control meal [32]. Another study that investigated the effects of non-fat milk 
against control beverages found serum triglyceride concentrations during the postprandial period 
did not differ between test meals [33]. However, vascular response as a potential mechanism in 
the postprandial state was not examined nor did they employ rigorous diet and exercise controls. 
Therefore, the present study is unique in that it employed proper dietary, as well as physical 
activity, controls both prior to and during the intervention. Additionally, in attempts to offer 
underlying mechanisms, ours is the first study to examine the postprandial vascular response to a 
high fat meal with non-fat milk. 
Our integrative physiological approach allowed us to gain insight into the potential 
mechanisms underlying the effects of dairy products on postprandial metabolism. While we did 
confirm our hypothesis that consuming one serving of non-fat milk with a high fat tolerance test 
(HFTT) would attenuate postprandial hypertriglyceridemia in individuals with a chronic high fat 
diet, we were unable to confirm that the improvement was associated with insulinotropic effects 
and the subsequent improvements in endothelial function and perfusion. In a previous study, 




(50g) of protein intake [85]. Perhaps the smaller protein content used in our trials (8g) was an 
insufficient stimulus for eliciting improvements in triglyceride-mediated endothelial dysfunction.  
One potential limitation of the present study was the use of strict control days. Diet and 
physical activity were carefully controlled prior to testing as they can modulate postprandial 
metabolism. However, one may argue that if participants had been allowed to consume their 
typical diet, an even greater benefit of milk might have been expected. Another potential limitation 
is that the serving size of fat consumed was relative to body weight meaning each participant 
consumed a different amount of fat.  Finally, the fat content in corn chips is more than 85% 
unsaturated fat. Therefore, we cannot extend these findings to meals high in the more metabolically 
harmful saturated fat. 
Clearly, the metabolic repercussions of repeated hyperlipidemic exposure elicits greater 
surges in postprandial triglycerides compared with a low fat diet. Importantly, the present findings 
are the first to confirm that non-fat milk is capable of attenuating postprandial hypertriglyceridemia 
in individuals who consume a high fat diet. Based on previous epidemiological studies, attenuating 
postprandial hypertriglyceridemia offers tremendous potential to reduce future CV risks. A single 
serving of non-fat milk with a typical Western diet offers a simple, convenient, and easily 
implemented option for managing elevations in postprandial triglycerides in individuals at risk for 
developing CVD.  
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Table 4. Selected Participant Characteristics. 
 
Variable Mean ± SEM 
Men/Women (n) 18/12 
Age (yr) 26 ± 1 
Height (cm) 172 ± 1 
Body Weight (kg) 93.6 ± 2.4 
BMI (kg/m2) 31.5 ± 0.8 
Total Body Fat (%) 39 ± 2 
Systolic BP (mmHg) 115 ± 2 
Diastolic BP (mmHg) 77 ± 2 
Total Cholesterol (mg/dl) 178 ± 7 
LDL Cholesterol (mg/dl) 108 ± 7 
HDL Cholesterol (mg/dl) 50 ± 3 
Triglycerides (mg/dl) 107 ± 16 
Blood Glucose (mg/dl) 93 ± 2 
  
(n=30); BMI = body mass index, BP = blood pressure, LDL = low density lipoprotein, HDL = 








Table 5. Changes in hemodynamic measures during the high fat tolerance test with carbohydrate 
control drink (CHO), caloric control drink (CAL), or non-fat milk (MILK). 
Measure Trial High Fat Tolerance Test 
  Baseline 120 min 240 min  
Mean BP (mmHg) CHO 83 ± 2 83 ± 2 85 ± 2 
 CAL 84 ± 2 83 ± 2 83 ± 2 
 MILK 83 ± 1 82 ± 2 82 ± 2 
     
Heart Rate (bpm) CHO 72 ± 2 74 ± 2 73 ± 2 
 CAL 71 ± 2 74 ± 2 74 ± 2 
 MILK 71 ± 2 72 ± 2 71 ± 2 
     
Brachial Flow-Mediated  CHO 7.8 ± 0.6 7.9 ± 0.7 9.1 ± 0.8 
Dilation (%) CAL 9.3 ± 0.8 8.3 ± 0.7 9.0 ± 0.9 
 MILK 9.0 ± 0.8 8.3 ± 0.8 7.9 ± 0.7 
     
Femoral Blood  CHO 476 ± 39 318 ± 26*  359 ± 49* 
Flow (ml/min) CAL 430 ± 33 400 ± 42 405 ± 45 
 MILK 465 ± 39 429 ± 63 321 ± 38*† 
     
Femoral Vascular  CHO 5.8 ± 0.5 3.9 ± 0.3* 4.3 ± 0.6* 
Conductance (AU)  CAL 5.2 ± 0.4 5.2 ± 0.6 4.9 ± 0.6 
 MILK 5.7 ± 0.5 5.6 ± 0.8 4.1 ± 0.5*† 
 




Table 6. Changes in circulating metabolic measures throughout the high fat tolerance test with carbohydrate control (CHO), caloric 
control (CAL), or non-fat milk. 
Measure Trial High Fat Tolerance Test 




CHO 97 ± 4 124 ± 5* 113 ± 6* 103 ± 5† 96 ± 5†‡ 94 ± 4†‡ 93 ± 4†‡§¶ 
CAL 95 ± 2 119 ± 5* 116 ± 5* 114 ± 5* 108 ± 6 102 ± 5†‡ 94 ± 4†‡ 
Milk 93 ± 3 121 ± 5* 112 ± 4* 113 ± 4* 101 ± 4† 95 ± 4†‡§ 97 ± 3†‡§ 




CHO 56 ± 5 465 ± 50* 472 ± 58* 334 ± 55*†‡ 280 ± 45*†‡ 177 ± 25*†‡§¶ 184 ± 24*†‡§¶ 
CAL 60 ± 9 469 ± 51* 382 ± 38*† 395 ± 49* 359 ± 45*†§ 236 ± 45*†‡§¶ 171 ± 31*†‡§¶ 
Milk 64 ± 9 525 ± 43* 408 ± 40*† 417 ± 46*† 290 ± 37*†‡§ 200 ± 29*†‡§¶ 183 ± 30*†‡§¶ 
         
 
GIP (pmol/L) 
CHO 26 ± 4 31 ± 4 34 ± 4* ______ 37 ± 5*† ______ ______ 
CAL 32 ± 7 35 ± 5* 32 ± 5 ______ 33 ± 5* ______ ______ 
Milk 28 ± 5 32 ± 5 35 ± 6* ______ 35 ± 6* ______ ______ 




CHO 38 ± 7 36 ± 7 39 ± 8 ______ 37 ± 7 ______ ______ 
CAL 38 ± 6 36 ± 7 34 ± 7 ______ 35 ± 6 ______ ______ 
Milk 38 ± 7 35 ± 7 36 ± 7 ______ 34 ± 6 ______ ______ 
         
 







Figure 4. Whole group triglyceride response 
A. Changes in plasma triglyceride concentrations during the high fat tolerance test 
(HFTT) with carbohydrate control drink (CHO), caloric control drink (CAL), and non-fat 
milk (MILK) (n=30). B. Changes in plasma triglyceride integrated area under the curve 
(iAUC) at 240 minutes during the HFTT with control drinks and non-fat milk. Values are 
mean ± SEM. 





















































Figure 5. Subgroup triglyceride response. 
 
A. Changes in plasma triglyceride concentrations during the high fat tolerance test 
(HFTT) with caloric control drink (CAL) and non-fat milk (MILK) in the low fat diet 
group (n=10) and B. high fat diet group (n=10). C. Changes in triglyceride integrated 
area under the curve (iAUC) between trials (CAL iAUC – MILK iAUC). Values are 
mean ± SEM.  




















































































REVIEW OF LITERATURE 
 
METABOLIC SYNDROME 
Metabolic Syndrome (MetS) is a constellation of interrelated metabolic risk factors 
that promote atherosclerotic cardiovascular disease and type 2 diabetes mellitus [1, 2, 86, 
87]. Underlying risk factors such as age, body weight, smoking, and inactivity contribute 
to the development of more serious metabolic risk factors including atherogenic 
dyslipidemia and elevated plasma glucose that commonly manifest as a pro-thrombotic and 
pro-inflammatory state [6]. The National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) identified 5 components that contribute to MetS: 
abdominal obesity (measured as waist circumference, men >102 cm; women >88 cm), 
triglycerides (≥150 mg/dL), HDL cholesterol (men <40 mg/dL, women <50 mg/dL), blood 
pressure (>120/>85 mmHg), and fasting glucose (≥110 mg/dL). When three of the five 
characteristics are present, a diagnosis of Metabolic Syndrome is confirmed [88]. The 
diagnosis of MetS was developed as a clinical measure for identifying individuals at risk 
for CVD and T2DM [89]. By concentrating on clinical causes such as obesity, 
hypertension, and dyslipidemia, it allows for the prevention of CVD and T2DM before the 
conditions are fully developed [3, 89]. 
In a population free of prevalent coronary heart disease (CHD), stroke, and T2DM, 
men and women with metabolic syndrome are ~1.5 and 2 times more likely to develop 
CHD than control subjects even after adjusting for age, smoking, LDL cholesterol, and 
race [90].  Findings from the Third National Health and Nutrition Examination Survey 
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(NHANES III) using 2000 census data show that about 47 million US residents have 
metabolic syndrome, an age-adjusted prevalence of nearly 24% [91]. As of 2006, the 
prevalence of MetS had increased to 34% and, considering this data is nearly a decade old, 
the current estimation is likely significantly higher [92]. The American Heart 
Association/National Heart, Lung, and Blood Institute recognize that insulin resistance and 
abdominal obesity are the predominant risk factors for Metabolic Syndrome [6].   
It has been suggested that obesity is the common mechanism linking metabolic 
syndrome. Abdominal obesity correlates strongly with insulin resistance and an unusually 
high release of non-esterified fatty acids from adipose tissue [93]. The resultant lipid 
accumulation at the liver and musculature further predisposes to both insulin resistance and 
dyslipidemia [94, 95]. Adipose tissue produces pro- and anti-inflammatory cytokines and 
other bioactive substances that appear to induce or maintain an inflammatory state, 
including activation of intracellular pathways that promote obesity and T2DM.  Lipid 
accumulation within adipocytes initiates cellular stress and activation of cell signaling 
pathways associated with inflammation including NF-KB. The NF-KB pathway regulates 
the proteins associated with the pathogenesis of both atherosclerosis and insulin resistance 
suggesting that obesity induced inflammation promotes both pathologies through common 
mechanisms and more importantly might be treated similarly [96]. Additionally, decreases 
in inflammation may down-regulate production of proteins involved in insulin resistance, 
T2DM, and CVD. Clearly, the increased adiposity associated with obesity maintains a state 
of chronic, low-grade inflammation that likely exacerbates MetS [46, 97]. 
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ATHEROSCLEROSIS AND INSULIN RESISTANCE 
  As mentioned above, two predominant risk factors for MetS are atherosclerosis and 
insulin resistance. Insulin resistance, a recognized hallmark of abnormal metabolic 
function, is characterized by excessive insulin secretion and/or impaired insulin signaling 
[6, 7]. Atherosclerosis is a form of chronic inflammation of the blood vessel walls that can 
lead to ischemia, end-organ damage, stroke, or myocardial infarction. Both the cause and 
effect of these pathologies are intricately connected with postprandial metabolism. While 
the mechanisms may differ, increasing severity of both insulin resistance and 
atherosclerosis contribute to the development of MetS and, eventually, CVD and T2DM.  
Atherosclerosis  
Atherosclerosis is responsible for one third of deaths world-wide and 42% of deaths 
in the U.S. [69, 96]. Atherosclerosis is the central pathological mechanism of vascular 
diseases including coronary artery disease (CAD), stroke, and peripheral vascular disease. 
The working definition of atherosclerosis is “a systemic dysfunctional endothelial, focal 
occurring, chronic inflammatory, fibro-proliferative, pro-thrombotic, angiogenic, 
multifactorial disease of the arterial intima caused by the retention of modified low-density 
lipoproteins, hemodynamic, and reductive-oxidative stress” [98]. 
There is consensus in the literature that T2DM and CVD are interrelated 
pathologies. Compared with non-diabetic subjects, those with diabetes have a two- to four-
fold increase in CAD and a greater extent of coronary ischemia [99]. In patients undergoing 
diagnostic coronary angiography, T2DM patients display more severe and diffuse coronary 
atherosclerosis [100]. In a population-based autopsy study, coronary atherosclerosis was 
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detected in 49% of diabetic decedents compared with 33% of those without diabetes [101]. 
These findings highlight the interrelated nature of CVD and T2DM, suggesting that they 
may be treated through similar mechanisms.  
 Pathophysiology of Atherosclerosis 
Atherosclerosis is considered a form of chronic inflammation resulting from a 
complex interplay between modified lipoproteins, immune cells, and the normal cellular 
elements of the arterial wall [1, 8, 102]. Pathogenically, it is a decades-long expansion of 
the arterial intima, the area between endothelium and underlying smooth muscle cells. The 
initial insult is the translocation of an LDL molecule into the sub-endothelial space where 
it becomes oxidized (becoming oxLDL). This initiates inflammation and immune 
responses, including the infiltration of T-cells, monocytes, and inflammatory cytokines [9]. 
The resulting complex lesions, or plaques, that protrude into the arterial lumen, are 
commonly known as fatty streaks. Eventually, monocytes and macrophages infiltrate the 
sub-endothelial space to phagocytize oxLDL and form foam cells that secrete further 
inflammatory markers [8, 103, 104]. Eventual plaque rupture and thrombosis result in acute 
clinical complications such as myocardial infarction and stroke [105]. While genetic and 
environmental factors have been identified in epidemiological studies, elevated serum 
cholesterols are sufficient to drive the pathogenesis of atherosclerosis independent of other 




Atherosclerosis and Vasculature 
The endothelium is the primary barrier against atherosclerosis. Lining the internal 
lumen of all vasculature, the endothelium is metabolically active and acts as the interface 
between blood and vascular smooth muscle cells. Through autocrine, paracrine, and 
endocrine mechanisms, the endothelium regulates vascular tone and structure while 
exerting anticoagulant, antiplatelet, and fibrinolytic effects [106, 107]. A healthy 
endothelium maintains vascular homeostasis by keeping atherogenesis in check in part by 
the contributions of nitric oxide (NO) [108] . 
Within endothelial cells, NO is synthesized from L-arginine by the enzyme eNOS. 
Shear stress within the vessel stimulates NO release from the arterial wall into the lumen 
and acts as a vasodilator to increase brachial artery diameter [11]. In addition to its role as 
a vasodilator, NO prevents thrombus formation and vasospasm as an inhibitor of platelet 
aggregation and smooth muscle cell proliferation, respectively [108]. Damage to the 
endothelium initiates the promotion and exacerbation of atherosclerosis including 
increased endothelial permeability, platelet aggregation, leukocyte adhesion, and cytokine 
production [1].  Eventually, the endothelium undergoes phenotypical alterations to this 
non-adaptive state known as “endothelial dysfunction” which manifests due to a loss or 
dysregulation of homeostatic mechanisms. Endothelial dysfunction is defined as the failure 
of the vascular endothelium to achieve its normal role of vasodilation and preservation of 
vascular homeostasis [109]. 
Endothelial dysfunction is an early marker for atherosclerosis and presents before 
angiographic or ultrasound evidence of plaques is detected [10]. It is characterized by 
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increased adhesion molecule expression, synthesis of pro-inflammatory or pro-thrombotic 
factors, oxidative stress, and abnormal modulation of vascular tone. Moreover, the balance 
between vasodilation and constriction is upset [110, 111].  Specifically, impaired 
vasodilation from decreased production or activity of NO is one of the earliest signs of 
atherosclerosis [112]. During the formation of an atherosclerotic plaque, oxLDL is retained 
within the intima of arteries, which activates endothelial cells and upregulates the 
expression of adhesion molecules and the secretion of chemokines [8, 103]. Normally, NO 
acts to prevent the oxidation of LDL [113].  However, the presence of oxLDL within the 
sub-endothelial space decreases NO production [114]. With the loss of NO production or 
activity, contributors to atherosclerosis are initiated including vasoconstriction, smooth 
muscle cells proliferation, and oxidative stress [115, 116]. Clearly, even the initial insult 
of atherosclerosis instigates endothelial damage and as the pathogenesis progresses, so too 
does the severity of vascular remodeling and subsequent dysfunction.  
Both plasma and macrophage content of oxLDL in coronary plaques correlate with 
the severity of acute coronary syndrome [117]. Studies using both physiological (via flow-
mediated dilation) and pharmacological (via acetylcholine) measures found endothelial 
dysfunction in patients that presented with risk factors for, but not ultrasound or 
angiographic evidence of, CAD [118]. Present at both conduit and microvascular levels, 
this confirms that endothelial dysfunction is present in the preclinical stages of 
atherosclerosis [11, 12]. In fact, coronary endothelial vasodilator dysfunction is an 
independent predictor of atherosclerotic progression and CV events even after adjusting 
for conventional risk factors [119]. In patients with and without CAD, acute cardiovascular 
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events are predicted by epicardial and microvascular coronary endothelial dysfunction 
[120]. 
Insulin 
The hormone insulin plays a central role in the regulation of glucose and 
triglyceride metabolism and is largely responsible for the maintenance of normal 
postprandial glucose concentration. With normal insulin sensitivity, an ingested 
carbohydrate load is shortly followed by a transient rise in plasma glucose and a 
proportional rise in insulin to maintain normal glucose homeostasis.  Insulin reduces this 
postprandial hyperglycemia by inhibiting hepatic glucose output and stimulating both 
glucose uptake and glycogen synthesis in skeletal muscle.  Insulin also plays an important 
role in triglyceride metabolism by stimulating fatty-acid uptake and storage in muscle and 
adipose tissue. Thus, the net effect of insulin is the attenuation of the rise in postprandial 
glycemia and triglyceridemia. 
 Insulin and Vasculature 
In addition to its metabolic effects, insulin plays a critical role in the regulation of 
blood flow in the vasculature. The primary mechanism by which insulin exerts its vascular 
effects is via endothelial cell production of NO. NO production induces vasorelaxation and 
increases capillary recruitment and blood flow in target tissues, specifically skeletal 
muscle. The end effect is augmented glucose disposal. Insulin infusion at higher 
physiological concentrations with a euglycemic clamp elicits a dose-dependent increase in 
skeletal muscle blood flow [121].  
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Insulin differentially modulates the vasculature tree. Initially, dilation of the 
terminal arterioles increases perfusion and capillary recruitment, followed by relaxation of 
the larger resistance vessels that increases overall limb blood flow. Animal and human 
studies have confirmed that this increased blood flow in skeletal muscle is due to the 
vasodilatory effects of NO production [122]. The vascular protective effects of insulin, 
including vasodilation, inhibition of vascular smooth muscle cell migration and 
proliferation, attenuating inflammatory cell infiltration, and inhibition of platelet 
aggregation, are all mediated by NO production in the endothelium [110].   
Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) are released from the small intestines upon the absorption 
of glucose. These hormones inhibit glucagon and stimulate insulin release, accounting for 
nearly half the rise in postprandial plasma insulin [123]. With normal insulin sensitivity, 
insulin, GIP, and GLP-1 inhibit hepatic glucose output, stimulate skeletal muscle glucose 
uptake, and facilitate intramuscular glycogen synthesis. The end result is a reduction in 
postprandial hyperglycemia.  
Insulin Resistance Pathophysiology 
Insulin resistance, characterized by excessive insulin secretion and/or impaired 
insulin signaling, is an abnormal metabolic function that may facilitate or prolong elevated 
postprandial plasma glucose and triglycerides and necessitates elevated insulin secretion. 
Abnormal insulin response leads to metabolic imbalances, including hyperglycemia, 
hyperinsulinemia, and hypertriglyceridemia that are maintained in a perpetual cycle of 
metabolic dysfunction. This imbalance also affects the release of GIP and GLP-1. In 
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individuals with diabetes, the effects of GIP are impaired or lost while those of GLP-1 are 
unaffected, which could contribute to decreased insulin production and prolonged states of 
postprandial hyperglycemia and hypertriglyceridemia. [124].   
The hypersecretion of insulin, such as in states of insulin resistance or caloric 
excess, inhibits the ability of insulin to attenuate postprandial hyperglycemia and 
hypertriglyceridemia. However, this is problematic because insulin is an inhibitor of fatty-
acid oxidation [125]. Thus, the low resting fat oxidation increases the risk of weight gain 
and obesity and is a determinant of the elevation in postprandial triglyceridemia [126, 127]. 
Insulin resistance has been implicated as an indirect cause of atherogenesis by promoting 
the development of dyslipidemia. Early in the pathogenesis of insulin resistance, free fatty 
acids increase due to the loss of the suppressive effects of insulin on lipolysis in adipocytes.  
Moreover, when there is increased fatty-acid uptake into skeletal muscle, as seen in obesity 
or insulin resistance, the absence of a relative increase in fat oxidation or storage may result 
in the accumulation of fatty-acid intermediates which further impairs insulin signaling 
[128, 129].   
Insulin Resistance and Vasculature 
The vasoregulatory action of insulin on endothelial cells stimulates the production 
of vasoconstrictors and vasodilators. Normally, insulin is protective and vasodilatory 
effects are mediated by NO production [130, 131]. Insulin resistance plays a major role in 
the onset of endothelial dysfunction by inducing a loss of vascular reactivity, impaired 
normal vasomotion, and reducing blood flow. These impairments, and the associated 
endothelial dysfunction, precede atherosclerosis [132-134]. It has been shown that 
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endothelial dysfunction is closely correlated with the presence of insulin resistance and that 
the effect of insulin on atherosclerosis is primarily mediated through its effect on other 
CVD risk factors, including dyslipidemia and hypertension rather than by a direct effect of 
insulin [134-136].  
In addition to the metabolic disturbance evident in insulin-resistant states, the 
vascular effects of the hormone are also impaired. Insulin-resistant rodent models have 
shown decreased eNOS activity, defective insulin signaling in vascular tissues, and 
impaired insulin action on endothelial cells [130, 137]. In humans, the simultaneous 
metabolic and vascular impairments to insulin resistance have been confirmed. The 
induction of acute insulin resistance by the infusion of free fatty acids causes acute insulin 
resistance and is characterized by a simultaneous decrease in glucose uptake and 
endothelium-dependent vasodilation [22]. The impairment of vascular responses is 
proportional to the degree of insulin resistance [36]. It is known that skeletal muscle 
vasodilation in response to insulin infusion is reduced in obese subjects and that differences 
in blood flow rates are most relevant within physiological insulin ranges [36, 138]. In 
patients with T2DM, insulin therapy improves endothelial function [139]. The finding that 
pharmacological interventions reverse endothelial defects supports the close relationship 
between insulin resistance and endothelial dysfunction. It is widely accepted that multiple 
independent and interdependent mechanisms induce a circle of dysfunction between 
insulin resistance and vascular dysfunction that explains the association between metabolic 
and vascular diseases [121].   
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POSTPRANDIAL METABOLISM AND ACUTE VASCULAR DYSFUNCTION 
  
In the past, clinical evaluation of hyperglycemia and hypertriglyceridemia as a 
measure of CVD and mortality has utilized fasting measures. However, this likely 
represents the nadir of daily blood glucose and triglycerides, respectively. Instead, it is 
becoming increasingly well accepted that atherosclerosis is a postprandial phenomenon 
[37]. Most humans eat every four to five hours, but it requires upwards of eight hours for 
complete clearance of glucose and triglycerides from the blood stream. This suggests that 
most humans spend the majority of their day in a postprandial state. Therefore, postprandial 
measures represent a more robust indication of daily plasma glucose and triglyceride 
exposure and a truer reflection of the associated risks [13, 15, 17, 18, 21, 140, 141].   
 
 Hyperglycemia 
Precise matching of glucose utilization with endogenous glucose production and 
dietary glucose delivery is required for maintenance of normal plasma glucose 
concentrations. In a fasting state, plasma glucose is relatively stable, indicating that 
production and utilization rates are equal [142]. After a meal, glucose absorption increases 
plasma glucose concentrations more than twice the rate of endogenous glucose production. 
Postprandial hyperglycemia depends on timing, quantity, and composition of the meal, the 
total amount of carbohydrate, the rate and degree of glucose absorption, the secretion of 
insulin, and inhibition of glucagon [143]. 
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Epidemiological studies have consistently shown that serum glucose levels two 
hours after an oral glucose challenge are significant predictors of CV risk [38]. These 
findings have been confirmed by two meta-analyses that have found that a 2-hour glucose 
challenge predicts CHD [13, 144]. Postprandial hyperglycemia has been identified as a 
possible independent risk factor for CVD by its association with intima-media carotid 
thickening [145]. Finally, serum glucose levels are associated with infarction prognosis in 
non-diabetic subjects [146], and postprandial glycemia is an independent risk factor for 
CHD in patients with T2DM [21]. 
An intervention study using subjects with impaired glucose tolerance determined 
whether an intervention to limit postprandial hyperglycemia would reduce the risk of CVD. 
Acarbose, an a-glucosidase inhibitor that specifically reduces postprandial hyperglycemia, 
was associated with a 34% reduction in risk of developing new cases of hypertension and 
a 49% risk reduction in CV events [147]. In addition, acarbose treatment is associated with 
a reduction in intima-media thickness in T2DM patients [148] as well as with a significant 
reduction in CV events independent of other risk factors [149]. In the progression of 
atherosclerosis, an LDL molecule enters the sub-endothelial space and becomes oxidized. 
LDL oxidation increases acutely after meals in T2DM further contributing to augment the 
degree of hyperglycemia, [150, 151]. Clearly, attenuating postprandial hyperglycemia may 




Hyperglycemia and Vasculature 
Acute hyperglycemia, independent of insulin levels, significantly attenuates 
forearm endothelium dependent, but not independent, blood flow in healthy humans [23]. 
In both diabetic and healthy subjects, hyperglycemic spikes have been shown to induce 
endothelial dysfunction. It is purported that these effects are linked with a reduced 
production or bioavailability of NO since the hyperglycemia-induced endothelial 
dysfunction is counterbalanced by arginine [152]. The rapid decrease in flow-mediated 
dilation (FMD), a measure of endothelial dependent vasodilation, is inversely correlated 
with the magnitude of postprandial hyperglycemia in T2DM subjects [153].  
Thrombin is a molecule involved in the coagulation cascade, alterations of which 
are linked to thrombosis. Postprandial hyperglycemia causes an overproduction of 
thrombin which has been shown to be strictly dependent on blood glucose levels [154]. 
Further, adhesion molecules regulate the interaction between endothelium and leukocytes 
and intracellular adhesion molecule-1 (ICAM-1), specifically, increases in subjects with 
diabetes and/or vascular disease. Postprandial hyperglycemia has been shown to be a 
sufficient stimulus for increased circulating levels of ICAM-1, thus activating one of the 
first stages of atherosclerosis [155, 156]. Finally, acute hyperglycemia has been shown to 






Lipoproteins are comprised of lipids and one or more apolipoproteins, the particle 
that interacts with cell receptors and enzymes [159]. Various lipoproteins are classified 
according to density and are involved in several metabolic processes: very low density 
lipoproteins (vLDL) and chylomicrons transport triglycerides from endogenous sources 
and exogenous sources, respectively, to peripheral tissues and HDL carries cholesterol 
from the periphery to the liver [160]. Lipoprotein lipase, present on the luminal side of 
endothelial cells, is responsible for the hydrolysis of triglycerides into glycerol and free 
fatty acids. After consumption of a high fat meal, chylomicrons carry triglyceride through 
the vasculature where fatty acids are liberated by lipoprotein lipase and taken up by 
surrounding adipose and muscle cells [161]. Triglyceride removal is dependent on LPL 
activity and the tissues’ need for lipids [162]. In a postprandial state, LPL availability 
becomes limited due to competition for binding sites and causes triglyceride rich 
lipoproteins, including chylomicrons, vLDL, and remnants, to accumulate [19, 163].  
In hypercaloric diets such as with Metabolic Syndrome, obesity, and T2DM, there 
is a chronic state of LPL competition and increased free fatty acids. The magnitude of 
postprandial plasma lipid increase is directly proportional to the fat content in meals [20, 
72, 73]. After a high fat meal, plasma triglycerides increase, peaking around four hours and 
returning to fasting levels around eight hours. Because a fatty meal increases plasma lipids, 




Increased plasma triglyceride results in reduced HDL and increased small, dense 
LDL. This contributes to an increased susceptibility to oxidation and a perpetual cycle of 
hypertriglyceridemia and atherosclerosis [164]. Plasma triglycerides are important 
determinants of plasma cholesterol metabolism, but evidence indicates that postprandial 
triglycerides are better predictors of atherosclerosis and coronary artery disease than fasting 
levels [14-17, 20, 140, 165]. The classification based on the magnitude of postprandial 
hypertriglyceridemia demonstrates a 68% accuracy in detecting the presence of CVD 
[166]. Postprandial triglyceride concentrations are associated with carotid artery wall 
thickness and represent an independent risk factor for atherosclerosis [141, 167, 168]. 
Dyslipidemia is a recognized risk factor for CVD in diabetes, and postprandial 
hyperlipidemia contributes to this risk [169, 170]. Every 1.13 mmol/L increase in 
postprandial hypertriglyceridemia is associated with an increase in relative risk of 1.4 for 
a myocardial infarct [171].  
 
 Hypertriglyceridemia and Vasculature 
Endothelial dysfunction is present in states of hypertriglyceridemia and 
hypercholesterolemia and is attributed in large part to reduced bioavailability of NO [70]. 
Though the exact mechanism for the reduced NO bioavailability is unknown, it could 
include any number of impairments to receptors, L-arginine use, concentration and activity 
of eNOS, release of NO, and NO diffusion [107].  Endothelial dysfunction is related to 
postprandial serum triglycerides after a high fat meal in middle aged men and women [71]. 
A study comparing a low and high fat meal found that the high fat meal transiently impaired 
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endothelial function and there was a negative correlation between mean triglyceride 
changes and endothelial dysfunction [172]. Moreover, the non-physiological infusion of a 
triglyceride emulsion induced a loss of vascular reactivity mediated by both endothelium-
dependent and endothelium-independent mechanisms [173]. Even in young, healthy men, 
postprandial triglyceride levels are closely associated with impaired brachial artery FMD 
after a high fat meal [174].  
Atherosclerosis is dependent on LDL, remnant lipoprotein concentrations, and 
perturbations on the vessel wall that influence the rate of arterial lipoprotein retention. 
Thus, both hypertriglyceridemia and hypercholesterolemia promote atherosclerosis and the 
associated vascular dysfunction [19, 20].  Atherogenic hypertriglyceridemia is due to 
impaired uptake of cholesterol remnants, not defective triglyceride hydrolysis [20]. Acute 
hypertriglyceridemia, induced by a high fat meal, correlates negatively with changes in 
FMD, but positively with changes in leukocyte O2- 
◦ production, a marker of oxidative 
stress. These changes were not seen with a low fat meal, indicating that acute 
hypertriglyceridemia causes endothelial dysfunction via at least a partial contribution from 
enhanced oxidant stress [175]. Hypercholesterolemia impairs the L-arginine pathway, 
through which NO is produced, by activating the angiotensin-II receptors to cause 
vasoconstriction and neurohumoral activation. This increases the release of reactive 
oxygen species thereby decreasing NO production and increasing vascular cell apoptosis 
and expression of adhesion molecules, chemotactic factors, and pro-inflammatory 
cytokines [104].  
 
 56 
The relationship between postprandial metabolism, vascular dysfunction, and 
metabolic diseases has been fairly well established. Considering that for most individuals 
in modern society, a majority of time is spent in a postprandial state, identification of 
treatments that moderate or attenuate postprandial hyperglycemia and 
hypertriglyceridemia is needed. Lifestyle modifications, including dietary interventions, 
offer an affordable and easily implemented alternative to pharmacological interventions. 
The hallmark risk factors of MetS, atherosclerosis, and insulin resistance, are postprandial 
by nature and so relevant research for MetS, CVD, and T2DM must include nutrition 
interventions that assess metabolic function. 
 METABOLIC AND VASCULAR EFFECTS OF DAIRY 
 
Bovine milk is comprised of approximately 87% water, 4-5% lactose, 3% protein, 
3-4% fat and less than 1% of vitamins and minerals combined. Milk supplies 32 grams of 
protein per liter.  Of the milk protein fraction, 20% is whey, a soluble protein, and 80% is 
casein, an insoluble protein. Both are considered high-quality proteins because they 
provide essential amino acids, are readily digested, and have high bioavailability. These 
two protein fractions differ in their amino acid profile. Whey protein is rich in branched 
chain amino acids (leucine, isoleucine, and valine) whereas casein is higher in histidine 
and phenylalanine. The fat fraction of milk, present as globules, is dependent on animal 
origin, stage of lactation, and feed-related factors. Typically, the fat found in milk is 
comprised of 98% triglycerides, of which 70% is saturated fatty acids and 30% is 
unsaturated fatty acids. Lactose, the carbohydrate found in milk, is a dissacharide sugar 
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comprised of galactose and glucose. The glycemic index of lactose is 45 compared with 
the reference 100 for glucose. In addition to the primary macronutrient composition, dairy 
products have a specific micronutrient composition including calcium, magnesium, and 
vitamin D [63].  
 
Epidemiological and prospective studies on dairy 
Epidemiological and prospective studies have found chronically high consumption 
of dairy products is associated with a reduced risk of diabetes and CVD.  Dairy intake is 
negatively associated with the risk of developing diabetes: individuals in the top quintile 
of dairy intake have a reduced risk of diabetes compared with those in the lowest quintile. 
Specifically, for each daily serving of dairy consumed there was a 9% and 4% decrease in 
risk of diabetes in men and women, respectively [24-26]. Further, milk consumption is 
inversely associated with the overall risk of CVD and stroke [74, 75]. There is a 15% lower 
relative risk for all-cause mortality and an 8% lower overall relative risk of ischemic heart 
disease with high dairy consumption [49]. Similarly, there is an inverse association 
between dairy intake and MetS development in healthy, overweight, and obese individuals 
[27, 28]. Compared with less than ten servings/week, consuming more than thirty-five 
servings/week decreased the odds of developing MetS by 72% and each daily serving of 
dairy reduces the risk of MetS by 21% [27]. 
These studies examining the relationship between dairy and MetS, CVD, and 
T2DM indicate that higher consumption of dairy elicits favorable effects on metabolic 
health. Since the pathologies are metabolic in origin and develop in a postprandial state, 
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investigating nutrition interventions are necessary to elucidate the potential physiological 
mechanisms regulating these relationships. 
 
Dairy and Glycemia  
 
 Long-term Intervention Studies 
Dietary intervention studies investigating the effects of milk or dairy products and 
glucose response are few; however, results from published trials indicate a range of effects, 
likely due to the different types of dairy employed. In a six-week randomized cross-over 
trial, subjects replaced 13% of their daily energy intake with either butter or cheese of 
equivalent fat content. Compared with the butter trial, fasting blood glucose increased after 
the cheese intervention. Authors admit this finding was unexpected and offer no 
explanation, but offer the evidence that insulin resistance values were no different between 
trials [176]. An eight-week clinical trial investigating the effects of low-fat dairy intake on 
overweight and obese men found no effect on fasting glucose concentration [177]. 
However, a 6-week randomized control trial found decreased plasma glucose 
concentrations with high dairy consumption compared with a control food in obese women 
[178]. Fasting blood glucose concentration did not change within or between trials in 
hypertensive subjects who consumed 4+ servings of low-fat dairy or eliminated all dairy 
for 4 weeks [179]. The discrepancy between the above mentioned studies are likely 
attributed to metabolic health of the subject population; in the previous study, subjects 
demonstrated elevated fasting glucose consistent with pre-diabetes (5.98-6.08 nmol/L) 
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whereas in the latter study, subjects exhibited normal fasting glucose levels (5.27-5.44 
mmol/L). While the long-term effects of dairy interventions are relevant to the treatment 
and prevention of metabolic diseases, postprandial studies provide descriptive information 
regarding mechanisms involved.  
 
Postprandial Intervention Studies  
The effects of dairy on postprandial metabolism indicate that milk elicits favorable 
effects on glucose metabolism both alone or with a meal. In a well-designed randomized 
cross-over study, whole milk (a control), a beverage based on equivalent milk 
macronutrients, complete milk protein (16g), lactose (24 g), or milk fat (16g) were 
compared for metabolic response.  Whole and simulated milk lowered blood glucose more 
than predicted by the sum of the area under the curve (AUC) for individual components 
[180]. Low fat milk reduced pre and post-meal peak blood glucose and post-meal glucose 
AUC compared with water, soy beverage, 1% chocolate milk, orange juice, or a cow milk-
based infant formula [51, 52].  
The majority of intervention studies examining postprandial metabolism and dairy 
employ milk derived proteins, specifically the now familiar supplement whey protein. The 
incremental area under the curve (iAUC) for glucose decreased in a dose dependent manner 
with the highest dose of whey protein supplement (20 g) having a significantly greater 
effect than lower doses on postprandial hyperglycemia from a 50g glucose drink [181]. 
Similarly, increasing doses of whey protein (10-40 g) pre-meal reduced post-meal blood 
glucose and insulin AUC in a dose dependent manner [53]. The combination of whey 
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protein and carbohydrate intake resulted in higher plasma insulin and reduced plasma 
glucose compared with those consuming carbohydrate alone [55]. A high glycemic meal 
for breakfast and lunch with whey protein increased serum insulin at breakfast 31% and 
lunch 57% compared with meals without whey. Further, the consumption of whey 
decreased postprandial serum glucose by 21% compared with the test meal without whey 
[41]. Individuals with diabetes who consumed 50 g of whey or placebo with a high 
glycemic breakfast and found glucose levels were reduced 28% and insulin increased 105% 
after the protein preload. Interestingly, while not compared in head-to-head fashion, these 
authors point out that the decrease in glycemia was a larger reduction than that observed 
after different doses of a rapid-acting non-sulfonylurea insulin secretagogue (18%) [54, 
182]. Clearly, whey protein consumption both in healthy and diabetic individuals 
attenuates the rise in postprandial glycemia when combined with a high carbohydrate load. 
 
Dairy and Lipemia 
Dyslipidemia is a significant risk factor for MetS, CVD, and T2DM and an 
increasing number of studies are examining the effects of long-term dairy consumption on 
the lipid profile. Of the total cholesterol pool, cholesterol carried by LDL is accepted as a 
better indicator of CVD risk due to the atherogenicity of LDL. Increased LDL is associated 
with increased consumption of SFA; however, a number of intervention studies using 
whole fat milk and other whole fat dairy products have not shown significant increases in 
LDL cholesterol [50, 183, 184]. Regarding the lipid profile, an increased proportion of 
small, dense LDL (sdLDL) particles represents a greater atherogenic risk than larger, less 
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dense LDL cholesterol molecules. In a cross-sectional study investigating healthy men, 
sdLDL particles were positively related to plasma triglycerides and fasting insulin levels 
and inversely to HDL. Individual fatty acids typically found in milk products were 
associated with fewer sdLDL particles suggesting milk’s fatty acids are associated with a 
more favorable lipid profile [185].  
 
Long-term Intervention Studies 
In a 10-year longitudinal study, a higher intake of dairy saturated fat was associated 
with a lower CVD risk compared with a higher intake of meat saturated fat. Interestingly, 
substitution of 2% of energy from meat SD with energy from dairy saturated fat was 
associated with a 25% lower CVD risk. The authors acknowledge that this attenuation was 
likely attributed to other components of dairy such as calcium, magnesium, and/or 
bioactive peptides, but it could have been due to a difference in the relative proportions of 
different saturated fatty acids in meat and dairy [186]. However, a five-year prospective 
study of three hundred women demonstrated that total dairy, milk, yogurt, cottage cheese, 
and calcium were positively related to triglycerides and negatively to HDL cholesterol at 
baseline, but no association was found for any five year changes [187].  Healthy 
normocholesterolaemic males who consumed 20% of dietary energy as butter for twenty-
one days showed no significant change in blood lipid or apolipoprotein profile [50].  
Studies show conflicting results regarding milk protein’s effects on lipid profiles.  
Whey protein isolate supplementation over three months significantly reduced fasting 
triglycerides, total cholesterol, and LDL cholesterol in overweight and obese adults [188]. 
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A similarly designed study employing a malleable protein matrix (protein enriched yogurt) 
reduced fasting triglycerides, and this effect was more pronounced in subjects with elevated 
triglycerides at baseline [189]. However, three-month supplementation with whey protein 
during a weight regain study showed no effect on plasma lipids [190]. In a study examining 
the effects of lactotripeptide supplementation with or without exercise on vascular 
measures, there was no change in lipid panel including total cholesterol, LDL, HDL, or 
triglycerides in postmenopausal women after eight weeks of lactotripeptide 
supplementation [191]. Though the number of studies are limited, the available evidence 
indicates that milk proteins may have a beneficial effect in individuals with poorer 
metabolic health.  
 
 Postprandial Intervention Studies  
Postprandial triglyceridemia is strongly influenced by the composition of the meal, 
including the quality and quantity of fat. To date, there are few studies examining the role 
of complete dairy products on postprandial metabolism [32, 33]. The majority of dairy and 
lipemia studies have examined the effects of milk-derived proteins on postprandial 
metabolism. Compared with control, the postprandial appearance of triglycerides was 
decreased 21% and 27% when a meal was consumed with whey and casein, respectively 
[77]. There was no difference between four milk-derived proteins on postprandial plasma 
triglycerides during an eight-hour high fat test [76].  Postprandial apolipoprotein B-48 (apo 
B-48) response to a high fat meal was significantly reduced when consumed with 60 g of 
whey protein compared with an equivalent dose of casein protein, independent of medium 
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chain SFAs. This reduced apo-B-48 is indicative of a reduced number of chylomicron 
particles within the blood stream suggesting the potential of dairy to reduce CVD risk 
associated with a high fat meal [192]. While acute studies examining the effects of milk 
proteins on lipid levels are spare, they agree in their findings of improved postprandial 
lipemia with addition of milk-derived proteins to a meal.  
 
Vascular Function and Dairy 
Long-term studies examining the effects of dairy in general suggest favorable 
effects on vascular function.  In a two-month study examining the effects of lactotripeptide 
supplementation with or without exercise on cardiovascular health in post-menopausal 
women, lactotripeptide supplementation, alone and with concomitant aerobic exercise, 
reduced blood pressure and improved flow-mediated dilation and arterial compliance [191, 
193].  A one-month study supplementing hypertensive subjects with specially formulated 
whey protein blend showed improvements in vascular reactivity as measured by flow-
mediated dilation, up 3% compared with baseline [194]. Compared with a control group, 
subjects who consumed both whey and casein with concomitant exercise demonstrated 
favorable changes in augmentation index and pulse wave velocity [195]. However, a study 
comparing intact whey, casein, and semi-skimmed milk in overweight adolescents found 
improvements in blood pressure, but failed to find significant changes in vascular measures 
of arterial stiffness, including augmentation index and pulse wave velocity [196]. However, 
arterial stiffness is an age-related disease so likely the subject population exhibited near 
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optimal values for augmentation index and pulse wave velocity. Thus the basement effect 
would have limited the potential benefits of dairy. 
Few studies have been conducted investigating vascular effects during the 
postprandial state with milk or milk proteins. Most of those studies employed measures of 
arterial stiffness as the vascular measure, specifically pulse wave velocity (PWV). PWV is 
a useful clinical measure as it is an independent predictor of CVD. However, significant 
changes in PWV occur primarily with chronic interventions making it a less-than-ideal tool 
for postprandial studies. Every study to date to evaluate the postprandial effects of milk 
proteins on arterial stiffness found no effects [77, 197, 198].  Flow-mediated dilation, a 
measure of endothelial-dependent vasodilation, may change acutely as it is depressed in 
hyperglycemic, hyperlipidemic, and hyperinsulinemic states [199]. Interestingly, in mild 
hypertensive, overweight subjects, FMD improved 4.3% at 120 minutes with a whey 
protein derivative compared with placebo [68]. There is no difference in NO dependent 
vasodilation in the microcirculation between milk and rice beverage control [200]. 
However, low-fat milk maintains conduit vessel vascular endothelial function in adults 
with MetS by limiting postprandial hyperglycemia when compared with rice milk [67]. 
The acute vascular effects of dairy in a postprandial setting have been minimally 
investigated, but the overall findings suggest a favorable response. FMD is a measure of 
endothelial-dependent vasodilation and improvements in FMD imply increased NO 
production and its protective effects. The potential for dairy to limit postprandial 
impairments in FMD indicates significant therapeutic applications for at-risk individuals.  
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However, the investigations into the vascular effects of dairy are still in an early stage and 
mechanisms of action have yet to be fully determined.  
 
 Mechanisms of improvement 
Protein 
Clearly, the beneficial effects of milk as seen in cross-sectional and epidemiological 
studies are supported by long-term clinical trials and postprandial intervention studies. 
Regardless of the outcome, nearly all studies attribute the favorable metabolic effects of 
dairy, at least in part, to the insulinotropic effects of milk proteins. Indeed, compared with 
other protein sources, milk demonstrates a larger insulin response up to 240 minutes post-
meal [30].  
The suggested mechanisms for improved glucose regulation include a protein-
induced increase in serum insulin when milk products are added to a meal high in 
carbohydrates. The high amino content, branch chain amino acids (BCAA) in particular, 
may modulate glucose levels by increasing postprandial insulin secretion. Interestingly, 
whey hydrolysate elicits higher insulin responses compared with whole milk [201] and 
intact whey protein  [202]. Likely, this is due to the partially-digested proteins in whey 
hydrolysate eliciting a faster release of insulin. Whey protein has been shown to increase 
GIP, which triggers the release of insulin from pancreatic beta cells [203]. Increased insulin 
secretion is especially important in T2DM as diabetic individuals typically experience a 
decreased insulin response to carbohydrates.   
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As with glycemic control, the lipid lowering effects of dairy are primarily attributed 
to the insulinotropic effects of dairy. Increased insulin during postprandial lipemia inhibits 
hormone-sensitive lipase and the release of hepatic FFA and stimulates lipoprotein lipase 
which hydrolyzes triglycerides for metabolism and storage [79].  
 
Fat 
While the protein content of dairy is typically the primary constituent associated 
with reductions in glycemia, evidence is emerging that points to dairy’s fat content as a 
potential contributor. In a cross-sectional study of more than 10,000 Brazilian adults, the 
intake of total dairy was inversely association with fasting glucose and postprandial 
glucose after adjusting for covariates. Interestingly, myristic acid (14:0), a long chain 
saturated fatty acid found in dairy foods, was the only apparent nutrient to mediate the 
association between dairy intake and glycemia indicating this SFA may play a role in 
improving glucose homeostasis [204]. This finding is supported by EPIC –InterAct case-
cohort study, which showed a positive relationship between myristic, palmitic, and stearic 
acid concentrations in plasma phospholipids and diabetes risk [205]. However, it is 
important to note that the glycemic control exerted by dairy products is evident in non-fat 
and low-fat dairy products. Thus, the potential role of milk fats in regulating glycemia is 
likely in addition to other mechanisms, such as the insulinotropic effects of proteins. 
Vitamins and minerals 
In addition to the potential mechanisms of protein and fat in altering metabolism, 
dairy also contains a number of bioactive compounds with functional properties. The 
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combined vitamin and mineral content comprises less than 1% of milk, but this rather small 
volume suggests significant metabolic effects. A systematic review and meta-analysis that 
examined the role of vitamin D and calcium in T2DM found associations between low 
vitamin D status, calcium, or dairy intake and prevalence for T2DM and MetS. 
Additionally, there were inverse associations with both T2DM and MetS for the highest 
vs. lowest dairy intake. Evidence from vitamin D and/or calcium supplementation suggest 
that they may play an important role in preventing T2DM in populations at high risk, 
including glucose intolerance [206]. 
The leading food source of vitamin D in the American diet is fortified cow milk, 
which contains ~100 IU/8 oz [207]. Evidence indicates that vitamin D may beneficially 
mediate MetS risk factors [208]. In fact, a recent review reported that serum vitamin D 
status is inversely related to MetS and a separate meta-analysis of eight cross-sectional 
studies found that higher serum vitamin D levels reduced the prevalence of MetS nearly 
50% compared with lower levels [81, 209].  
The suggested mechanisms for the effect include reduced dyslipidemia and 
increased insulin production [81]. NHANES-III data show that plasma triglyceride levels 
are lower in individuals with >92.5 nmol/L of vitamin D compared with those with <62.5 
nmol/L [210]. Additionally, several intervention studies have shown improved glycemic 
responses with vitamin D treatment, but these effects may be specific to individuals who 
were deficient at baseline or those who had preexisting metabolic disorders [65, 211, 212].  
The relationship between higher dairy intake and reduced risk of stroke, all-cause 
mortality, T2DM, and ischemic heart disease, compared with lower total dairy intake has 
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not been fully elucidated, but it has been proposed that the high calcium content and lipid 
fractions in dairy benefits the serum lipid profile. Nearly half of the calcium in the 
American diet is from dairy [207]. Several randomized control trials have shown beneficial 
effects from calcium supplementation on plasma lipids [213-215]. Compared with 
consuming their standard diet, participants who consumed 2,200 mg/d of calcium from 
fortified foods for 10 days demonstrated decreased total cholesterol and LDL [213]. Serum 
cholesterol has been reduced by 15.4 mg/dL and triglycerides reduced 32.2 mg/dL with 
calcium supplementation (900 mg/day). The proposed physiological mechanism is that 
calcium binding to saturated fatty acids within the intestines forms insoluble soaps that are 
excreted in the feces. Healthy men consuming 1 L of milk or yogurt daily containing 1,200 
mg calcium compared with placebo demonstrated increased fecal fatty acid and bile acid 
excretion during dairy intake. This resulted in lower fat absorption compared with the 
placebo [82].  
Magnesium has also been proposed as a significant mediator in postprandial 
metabolism. Upwards of 10% of the magnesium in the American diet comes from dairy 
[63]. Data from epidemiological studies has consistently demonstrated an inverse 
relationship between magnesium and risk for incident insulin dependent and non-insulin 
dependent diabetes [216-218]. Clinical trials have demonstrated that oral magnesium 
supplementation has improved insulin sensitivity, glucose homeostasis, and HbA1c levels 
in diabetic patients [219].  Moreover, a meta-analysis of randomized control trials found 
12 weeks of supplementing with magnesium significantly lowered fasting serum glucose 
in T2DM patients (186). The mechanism is attributed to improved insulin elicited glucose 
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uptake because magnesium is essential for optimal coupling and signaling through the 
insulin receptor. Regarding dyslipidemia, magnesium has been shown to reduce serum 
triglycerides, apolipoprotein B, LDL, total cholesterol, and to increase HDL in patients 
with ischemic heart disease [83, 220, 221]. These effects have been attributed to 
involvement of modifications of several enzymes intricately linked with lipid metabolism 
[84].  
Dairy’s micronutrient profile offers significant potential for favorable effects on the 
cardiometabolic profile. As with the insulinotropic effects of milk proteins, evidence 
suggests that these micronutrients offer their greatest benefits to individuals who are either 
deficient in the respective vitamin or mineral or who are farther along the spectrum of 
disease progression. However, their mechanisms of action have yet to be fully described 





APPENDIX A: 3-DAY FOOD LOG 
 
3-Day Food Intake Record Instructions 
 
1. Record day of the week and date for everything you eat and drink for three days 
(two week days & one weekend day) prior to arriving at your appointment.   
2. Include the time, amount and type of food/beverage consumed. Provide as much 
detail as possible, including brand names when available. For example, instead of 
recording “cereal with milk”, record “1.5 cups Kashi GoLean cereal with 6 oz 
low-fat milk”. Instead of “1 slice wheat toast with jam”, record “1 slice Orowheat 
100% whole-wheat toast with 1tsp Smucker’s low-sugar strawberry preserves”. 
See sample food log for more examples.  
3. For combination foods such as chili, soup, casseroles, sandwiches, list all items in 
the food and amounts of each item.   
4. For dairy products (milk, cheese, yogurt, etc) record whether, regular (whole), 
lowfat (1%), reduced fat (2%), or nonfat (skim).  
5. Include sweeteners (sugar, honey, syrup, etc) and fats (cream, half&half, milk, 
etc) added to coffee, tea, etc; as well as spreads on breads and dressings on salads.  







Sample 3 Day Food Intake Day of Week: Date: 
Time Amount Brand Food/Beverage 
  8am 8 oz  Nonfat milk (in cereal) 
 
12 oz  Black coffee 
 
1 Tsp  Sugar in coffee 
 
1.5 Cups Nature’s Path Heritage Heirloom Whole Grains 
Cereal 
 
1 T Sun-Maid Fruit bits 
 
1 medium  Cara Cara navel orange 
12pm 
1.3  Cups Homemade Chili: ½ Cup 70% lean ground beef, 1 
T onion, 2 T garbanzo beans, 2T black 
beans, 2 T red sweet pepper 
 3 T  Grated cheddar/jack cheese, regular 
 ½ Cup  Fresh strawberries 
 ½ Cup Stoneyfield Lowfat vanilla yogurt 
 2 T  Raw almonds 
3pm 1 Cliff Chocolate Builder’s Bar 
6pm 5 oz  Grilled chicken breast, skinless 
 
¾ Cup  Slaw:  ¼ cup cabbage, ¼ grated 
carrots, ¼ broccoli, 1 tsp olive oil, 1 
tsp cider vinegar 
 1 piece Kirkland Signature Multigrain bread 
 ½ tsp  butter 
 
¾ Cup  Grilled vegetables:  ¼ cup yellow 
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APPENDIX B: CONTROL DAY ACTIVITY AND DIET RECORD 
 
Subject ID:__________________________________Pedometer #:________________ 
 Time Steps    
Meal 1: ___________ ___________ Meal 1: ___________ ___________ 
Food #1   Food #1   
Food #2   Food #2   
Food #3   Food #3   
Food #4   Food #4   
      
Meal 2: ___________ ___________ Meal 2: ___________ ___________ 
Food #1   Food #1   
Food #2   Food #2   
Food #3   Food #3   
Food #4   Food #4   
      
Meal 3: ___________ ___________ Meal 3: ___________ ___________ 
Food #1   Food #1   
Food #2   Food #2   
Food #3   Food #3   
Food #4   Food #4   
      
Meal 4: ___________ ___________ Meal 4: ___________ ___________ 
Food #1   Food #1   
Food #2   Food #2   
Food #3   Food #3   
Food #4   Food #4   
      
Total Step 
Count: 
                        
___________ 
 Total Step 
Count: 
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